<DOC>
	<DOCNO>NCT02264236</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy investigational agent , P10s-PADRE , peptide mimotope-based vaccine , patient race stage IV Non-Small Cell Lung Cancer complete primary chemotherapy without progressing , still measurable residual disease . A randomized double-blind placebo-controlled trial design goal evaluate efficacy vaccine . Efficacy base primarily tumor response , secondarily progression-free survival . Information safety tolerability collect . Humoral cellular immune response analyze .</brief_summary>
	<brief_title>Vaccination Stage IV NSCLC Patients With Carbohydrate Mimotope Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>stage IV NonSmall Cell Lung Cancer complete primary chemotherapy achieve either stable disease partial response measurable residual disease Women pregnant breastfeeding . Patients autoimmune disease immunosuppressed receive systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>